Stamp prices to go up 1 cent in January

The cost of stamps will go up by at least one cent in January. Maybe more.

WASHINGTON (CNNMoney) Mailing a letter will cost one cent more, or 47 cents, starting in January, under a proposal approved by the U.S. Postal Service's regulator.

The Postal Regulatory Commission ruled Thursday that the agency can raise the price in keeping with the cost of inflation. Prices could go even higher as the commission is considering a postal service proposal to raise money.

The U.S. Postal Service had asked for a total price hike of another 3 three cents, which would ultimately make first-class mail stamps cost 49 cents.

The price of sending a postcard would remain the same, at 33 cents, although the postal service is seeking to hike rates to 34 cents as part of its broader rate hike request.

The one cent hike will kick in Jan. 26.

If the agency gets the green light for all its rate hikes, it will mean an extra $2 billion for the cash-strapped postal service.

  No Saturday mail? USPS chief responds

The agency said last week it lost $5 billion in the latest fiscal year ending Sept. 30, far less than in recent years. In 2012, it reported a $16 billion loss.

Much of its cash problems stem from a congressional mandate to make annual $5 billion payments for future retiree health care benefits.

The requirement has been a major drag on the agency, which has exhausted a $15 billion loan from taxpayers to make up for shortfalls.

Declining mail volume continues to plague the postal agency. Some 2 billion fewer pieces of mail were sent in 2013 compared to 2012, thanks to another drop in first-class mail, the kind most consumers use to pay bills and send letters to Grandma.

This would be the second year in a row when the price of a a first-class mail stamp is going up by by 1 cent in January.

How do investors benchmark their bond funds?

A: There are two way to look at it. One is that when you invest in a bond fund the worst thing you should do is to look at historical return because these return already come in and they is no guarantee that this fund will deliver similar kind of return. Unlike equity, in a bond you need to look at simple thing that what is the current portfolio maturity and what is the current portfolio yield and if you invest in that product and have that kind of maturity yield and if you stay invested in that fund for that period then yield minus expenses you are going to get it.

If you look at liquid right now, liquid fund have a 60 days maturity, current portfolio yield is 10 percent plus, 25 bps expenses, you are going to get 9.75 to 10 percent for next 60 days. Similarly if you look at accrual products, which are one year plus kind of products where current yield is anything between 11 to 11.5 and 12 percent. You take 1.5 percent expenses, 10 percent plus kind of return you get, suppose you stay invested for one year period, so that is a way one need to look at.

Technically I can answer you that it has to be benchmark against the bond index and all that which for a normal investor doesn't matter. I think the real benchmark for a bond is to look at company FDs. If you have one year company FD, if you have three year company FD and you have product which is one year maturity or three year maturity then that product yield to maturity (YTM) has to be higher than the bank deposit.

Top BD Execs Predict What the Industry Will Look Like in 10 Years

A panel of top BD executives gave their predictions on what the industry will look like 10 years from now — as well as what it will take for advisors and broker-dealers to survive that long.

Tony Batman, chairman and CEO of 1st Global, said that hybrid advisors were best suited to serve clients’ many needs. Amy Webber, president and COO of Cambridge Investment Research, agreed that the hybrid model was the “best” one.

Both Batman and Wayne Bloom, CEO of Commonwealth Financial Network, also agreed that those advisors who can master wealth decumulation — as accumulation becomes passé for retiring clients — will fare well. Advisors who can successfully move from the accumulation phase to the decumulation phase and “do this well and provide retirement income will generate assets,” Bloom said.

Added Batman: “Wealth decumulation is complicated, but our industry is the only one with the answers.”

While all three noted the importance of technology to firms’ survival, Bloom noted that advisors will also be dealing with a “different set of clients,” and that they will have to develop “new communication skills.”

Top Blue Chip Stocks To Watch Right Now

Webber added that while clients will change, the make-up of firms will have to change as well. The “most successful” advisors will have “three generations” of advisors working there, and also more women.

Batman pointedly noted the industry’s failure to go after the next generation of clients: “One in 4 of top 1% of earners are under age 40 — they are income-rich and are totally neglected.”

---

Check out ‘Improving’ FINRA Among Top Goals for BD Lobby on ThinkAdvisor.

September existing home sales fall 1.9%

Existing home sales slipped 1.9% in September due to higher mortgage rates and prices, the National Association of Realtors said Monday.

The association says sales of re-sold homes fell 1.9 percent last month to a seasonally adjusted annual rate of 5.29 million. That's down from a pace of 5.39 million in August, which was revised lower. The sales pace in August equaled July's pace. Both were the highest in four years and consistent with a healthy market.

The report comes amid signs of slowing in the housing recovery.

Nationwide, home values were up 1.2% in the third quarter from the second, Zillow data show. That's down from a 2.5% jump in the second quarter from the first.

Top 5 Companies To Buy Right Now

Higher interest rates, fewer investor buyers and more homes for sale are all contributing to smaller price gains, economists say.

Last week, 30-year fixed rate loans averaged 4.28%, up from 3.37% a year ago, Freddie Mac said.

The government shutdown that ended last week and the related debate over raising the debt ceiling will also likely have an adverse effect on October home sales, says Leslie Appleton-Young, economist for the California Association of Realtors.

The association said last week that California home sales declined in September for the second straight month.

Contributing: The Associated Press

Oppenheimer Cuts Refiners on Deteriorating Earnings Outlook

Oppenheimer’s Fadel Gheit and Robert Du Boff have become the latest analysts to offer their opinion of refining stocks, when they downgraded Holly Frontier (HFC), Marathon Petroleum (MPC), Phillips 66 (PSX), Tesoro (TSO) and Valero (VLO) to Perform from Outperform today.

AFP

Gheit and Du Boff explain their cuts:

We are lowering our ratings for refining stocks…on a deteriorating earnings outlook, and are removing our price targets for the stocks…We are cutting our 3Q13 earnings estimates for the group to reflect weaker market crack spreads, notably for gasoline, a narrowing Brent-WTI spread, and lower sequential margin capture rates. Margin capture should be down for a variety of reasons, including the cost of RINs (~$0.85/g, up slightly from 2Q13), planned and unplanned downtime, pipeline constraints, and the shift in the oil market structure from contango to backwardation, which implies higher crude acquisition costs relative to benchmark cracks. While we note crude differentials began to widen in September, this will not have a positive impact on the bottom line for the quarter because of the lag time in crude purchases, typically 1-2 months.

The cuts follow Citigroup’s upgrade of Valero and Tesoro on Oct. 2, and Deutsche Bank’s pessimistic outlook on refiners from Sept. 10.

Holly has dropped 0.4% to $41.63, Valero has gained 0.2% to $34.17, Tesoro has advanced 1.6% to $44.47, Phillips is off 0.9% at $59.03 and Marathon is up 0.2% at $65.36.

5 Rocket Stocks to Buy for September Gains

BALTIMORE (Stockpickr) -- Investors didn't see it coming last Wednesday, when Bernanke and company at the Fed announced that the taper talk was being, well, tapered. And markets have been playing catch-up ever since.

>>How to Win With the Twitter IPO

With the winding down of QE postponed (at least for a little while longer) investors can turn their attention to more pressing matters: like yet another debt ceiling gun to Uncle Sam's head. Left unsettled, the government shutdown would kick off on Oct. 1.

I'll make a bold prediction: Politicians on both sides will prolong the drama until the last possible second, and then they'll resolve things by deciding to figure it out later on. The key difference between now and the last go-around is that at least the markets are getting used to the conspicuous dysfunction on Capitol Hill. In fact, some names are well positioned to rally into the end of September.

To get the most bang for our buck this week, we're turning to a new set of Rocket Stocks.

>>5 Stocks Ready to Break Out

For the uninitiated, "Rocket Stocks" are our list of companies with short-term gain catalysts and longer-term growth potential. To find them, I run a weekly quantitative screen that seeks out stocks with a combination of analyst upgrades and positive earnings surprises to identify rising analyst expectations, a bullish signal for stocks in any market. After all, where analysts' expectations are increasing, institutional cash often follows. In the last 215 weeks, our weekly list of five plays has outperformed the S&P 500 by 90.7%.

Without further ado, here's a look at this week's Rocket Stocks.

Visa

2013 is panning out to be a stellar year for payment network giant Visa (V): Shares of the $128 billion firm have rallied more than 31% since the calendar flipped over to January. As consumers continue to show signs of strength, Visa should continue to show its shareholders the same.

>>5 Big Trades to Take as the Fed Hits the Gas

Visa is the biggest name in payments. The firm's logo is printed on more than 60% of the world's credit and debit cards, a share of the market that's more than double that of its closest rival. In a lot of ways, payment card acceptance is a positive feedback loop: consumers see Visa's network accepted everywhere they shop, so they're more likely to get a Visa-braded card, and merchants see more customers use Visa than any other brand, so they're more willing to keep accepting Visa. That makes the firm's network extremely hard to replicate for new networks unless they're willing to take a huge haircut on the fees they charge.

Because Visa is the network, not the card issuer, it doesn't carry credit risk on its balance sheet from consumer borrowers. Visa facilitates the transaction, but it doesn't lend the money. As consumers shift continue their payments from predominantly cash and checks to predominantly electronic credit or debit card payments, the market should get bigger quickly enough for all of the participants to benefit. Visa's massive scale just means that it'll get to benefit more.

Goldman Sachs

Let's face it, people love to hate Goldman Sachs (GS). In a lot of ways, Goldman was the posterboy for the problems of Wall Street that led to the financial crisis of 2008. But none of that changes how well GS has been executing in 2013.

>>5 Stocks Insiders Love Right Now

Goldman Sachs is a diversified investment bank whose businesses include investment management, prime brokerage, and research on top of its traditional book-running. Think what you will of the regulations enacted since 2008, the smaller pool of large investment banks after the Great Recession means that GS automatically claims a bigger share of the market. Beyond that, the firm's reputation as a well-connected industry name holds a lot of cachet with many clients, particularly in the investment management side of the business, where wealthy retail clients want the Goldman Sachs name on their statements.

The firm's decision to become a bank holding company is likely to continue to constrain the level of risk that the firm is able to take on. The increased scrutiny isn't necessarily a bad thing -- it helps to prevent Goldman from conspicuously over-leveraging itself in chase of returns. The financial performance that GS has turned out in 2013 isn't likely to change much in the foreseeable future.

Blackstone Group

Another financial sector giant on our list of Rocket Stocks this week is Blackstone Group (BX). Best known as a private equity firm, Blackstone actually offers its clients exposure to a wide array of alternative investments, ranging from those well-known private equity funds to real estate and hedge funds. As skittish high-net worth investors chase low-correlation investments in a market that's seen its share of scares, BX should continue to attract capital.

>>5 Stocks Under $10 Set to Soar

Blackstone's expertise in the private equity world gives it some big advantages. Unlike managers of public equity, PE firms take a more hands-on role with management of their portfolio firms, providing a mix of advice and outright orders. Blackstone's scale also means that it's able to pursue big deals that its smaller peers would need partners for.

The more conventional asset management business at BX is worth paying attention to as well. The firm runs one of the biggest real estate funds on earth as well as a colossal fund of funds, giving it major economies of scale that provide the flexibility to keep costs lower, greatly reducing what can often be one of the biggest barriers to meaningful returns for these types of investments.

As this equity rally continues to propel stock prices, Blackstone's unique menu of alternative investments should become increasingly important for investors.

Cognizant Technology Solutions

Cognizant Technology Solutions (CTSH) helps companies outsource high-cost IT services that range from software development to computer network maintenance. The firm has a pretty simple sales pitch: The company has a workforce with advanced technology expertise who work for less money than their Western counterparts. But it's how CTSH executes on that plan that makes it a unique name in the space.

>>4 Tech Stocks Triggering Breakout Trades

Cognizant isn't the only Indian IT outsourcer out there. But it was one of the first Indian IT outsourcers to plant its base of operations here in the U.S. with a management team that's able to flatten cultural barriers to doing business from the onset. It combines outsourced low-level services (with huge labor cost savings) with localized consulting efforts. That gives Cognizant the flexibility to market multiple services to each client it serves, and the firm earns hefty profit margins for its trouble.

CTSH has a mature customer base in North America, but a less mature base in the Eurozone, where it's still got ample growth opportunities. Global IT needs have far exceeded global IT budgets for the last decade, and that trend is accelerating, not abating. As long as Cognizant helps to stretch those IT dollars, it should continue to perform well.

Delphi Automotive

Another industry with huge tailwinds right now is automotive -- new-car sales continue to drive record numbers at automakers, spurred on by a combination of a record-aged auto fleet and record low interest rates. And auto parts supplier Delphi Automotive (DLPH) is one of the best ways to capitalize on that trend.

5 Best Industrial Conglomerate Stocks To Own Right Now

Delphi is one of the biggest auto parts suppliers for original equipment manufacturers, supplying everything from electrical components to safety products to powertrain modules to car factories around the world. Delphi got its start as a unit of General Motors (GM), and the Detroit giant still makes up around 20% of the firm's total sales. That means that the resurgence in the U.S. car industry specifically benefits Delphi in a big way.

Since Delphi provides car systems, not just simple parts, switching costs are high for its customers. Automakers can't go to another supplier without re-engineering its vehicles, and because of that, DLPH has a nice economic moat around its business. That, and the scale advantages of Delphi's size, provide a one-two punch that should keep its business performing at a high level for the rest of the year. Delphi has certainly had some missteps in the last decade, but it's healthier than ever before in 2013. With rising analyst sentiment in this Rocket Stock, we're betting on shares.

To see all of this week's Rocket Stocks in action, check out the Rocket Stocks portfolio at Stockpickr.

-- Written by Jonas Elmerraji in Baltimore.

RELATED LINKS:

>>5 Biotech Stocks Under $10 on the Move

>>5 Stocks Rising on Unusual Volume

>>Beat the S&P With These 5 Shareholder Yield Champs

Follow Stockpickr on Twitter and become a fan on Facebook.

At the time of publication, author had no positions in stocks mentioned.

Jonas Elmerraji, CMT, is a senior market analyst at Agora Financial in Baltimore and a contributor to

TheStreet. Before that, he managed a portfolio of stocks for an investment advisory returned 15% in 2008. He has been featured in Forbes , Investor's Business Daily, and on CNBC.com. Jonas holds a degree in financial economics from UMBC and the Chartered Market Technician designation.

Follow Jonas on Twitter @JonasElmerraji

10 Best Medical Stocks To Watch For 2015

It's not an uncommon situation. While investors are scouring the news (or lack thereof) from a company, they're not paying much attention to the stock itself. Big mistake, as stocks can and do have a life of their own, sometimes independently of the company. Vermillion, Inc. (NASDAQ:VRML) is the most recent example of this alarming disconnect. While news from the company of late has been fairly benign and a little non-existent, shares of VRML has been inching towards a key technical line in the sand that if crossed under could spark a fairly rapid selloff.

First things first. For those not familiar with the company, VRML is a medical diagnostic stock. Specifically, Vermillion is best known for its ovarian cancer test OVA1, which can determine if on ovarian mass is malignant. It's not the only test the company has on the market, however - it's just the flagship product. Also in Vermillion's product library is the OVA2 test, which is currently in development as a tool that could pinpoint other ovarian-cancer-related problems that OVA1 can't, and the VASCLIR test, which is also currently in development as a means of determining and individual's risk of peripheral artery disease.

10 Best Medical Stocks To Watch For 2015: Inergetics Inc (NRTI)

Inergetics, Inc., formerly Millennium Biotechnologies Group, Inc., incorporated on November 9, 2000, is a holding company for its sole operating subsidiary, Millennium Biotechnologies, Inc. (Millennium). The Company through its subsidiary Millennium, engages in the research, development, and marketing of specialized nutritional supplements as an adjunct to medical treatments for select medical conditions, as well as for athletes seeking improved recovery and advanced performance. The Company markets products, which are targeted toward immuno-compromised individuals undergoing medical treatment for diseases, such as cancer, as well as wound healing and post-surgical healing and geriatric patients in long-term care facilities among other conditions. In January 2013, the Company acquired Bikini Ready and SlimTrim brands from Whole Products Group.

The Company�� product portfolio include, Resurgex Select, Ready-To Drink Resurgex Essential and Ready-To-Drink Resurgex Essential Plus. Resurgex Select is a whole foods-based, calorically dense, high-protein powdered nutritional formula developed for cancer patients undergoing chemotherapy or radiation treatments. Resurgex Essential and Resurgex Essential Plus represent Millennium�� Ready-to-Drink product line and are being sold into the Long-Term Care geriatric markets.

Resurgex Select

Resurgex Select is a whole foods-based nutritional product that is designed to be used throughout the course of cancer treatment (chemotherapy, radiation, etc.), as many times patients lose weight and cannot consume adequate nutrition. This product combines dietary fiber (3 g), low sugar (5 g), and high protein (15 g) with no added antioxidants to be a high-calorie (350 calorie) supplement. It is available in three flavors (Vanilla Bean, Chocolate Fudge, and Fruit Smoothie) and each can be mixed with water, milk, juices, or in soft cold foods, such as yogurt, apple sauce or pudding.

Surgex

Surgex (www.surgexspor! ts.com), is a nutritional support formula that aims to address the concerns of many elite athletes who suffer from symptoms, such as fatigue, lean muscle loss, lactic acid buildup, oxidative stress, and stressed immune systems. This formula is designed to improve recovery parameters in efforts to enhance the performance of professional and collegiate athletes.

Resurgex Essential

The Essential line is a ready-to-drink alternative to Ensure and Boost designed to be marketed into the long-term care channel. Resurgex Essential has 250 whole food calories containing no corn syrup or corn oil. The product also contains fruit and vegetable extracts, and FOS Fiber to provide calories and taste.

The Company competes with Nestle and Abbott Laboratories Inc.

10 Best Medical Stocks To Watch For 2015: Scancell Holdings PLC (SCLP.L)

Scancell Holdings PLC is a United Kingdom-based company. The Company�� principal activity of the consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer. In April 2012, the Company completed recruitment to the Phase 1 clinical trial of SCIBI. In May 2012, the Company commenced recruitment and treatment of the first patient in the second part of it Phase 1/2 clinical trial of SCIBI. The Phase 2 part of the trial is conducted in five United Kingdom centers in Nottingham, Manchester, Newcastle, Leeds, and Southampton. On August 15, 2012, the Company announced the development of a platform technology, Moditope.

Top Consumer Stocks For 2015: RXi Pharmaceuticals Corp (RXII)

RXi Pharmaceuticals Corporation (RXi), incorporated on September 8, 2011, is a development-stage company. The Company is a biotechnology company focused on discovering, developing and commercializing therapies addressing medical needs using RNA interference (RNAi)-targeted technologies. As of July 12, 2012, RXi was focusing on its internal therapeutic development efforts in fibrosis. RXI-109 is its RNAi product candidate, which is a dermal anti-scarring therapy that targets connective tissue growth factor (CTGF). The Company�� therapeutic platform consists of two main components: RNAi Compounds (rxRNA) and Advanced Delivery Technologies. RNAi compounds include rxRNAori, rxRNAsolo and sd-rxRNA, or self-delivering RNA. On April 26, 2012, it completed the spin-off transaction from Galena Biopharma, Inc. (Galena).

In January 2011, the Company announced research results in collaboration with Generex Biotechnology Corporation, and RXi�� wholly owned subsidiary Antigen Express, Inc., in developing vaccine formulations for immunotherapy. In January 2011, it announced initial results as part of its collaboration with miRagen Therapeutics, Inc. in creating microRNA mimics, or artificial copies of microRNAs, using the Company�� sd-rxRNA technology. In February 2011, it announced the initiation of RXi�� development program for RXI-109.

10 Best Medical Stocks To Watch For 2015: AmbiCom Holdings Inc (ABHI)

AmbiCom Holdings, Inc. (AmbiCom Holdings), formerly Med Control, Inc., incorporated on July 1, 2008, through its subsidiaries, is engaged in design and development of wireless products focusing on the wireless medical industry. The Company was a development-stage company organized to sell a product called Med Time, an electronic and portable device aimed to control the doses and schedules of medications taken by elderly individuals. On January 15, 2010, the Company completed the acquisition of AmbiCom Acquisition Corp. (AmbiCom). AmbiCom is a holding company whose operating company, AmbiCom, Inc., is a designer and developer of wireless products focusing on the wireless medical industry. AmbiCom purchases standard wireless products and designs and develops features and packaging to customize these products to their target original equipment manufacturer (OEM) markets. AmbiCom�� wireless device solutions and applications include infusion pumps, heart monitoring machines, and glucose meters.

AmbiCom sells its products through multi-channel distribution and original equipment manufacturer (OEM) channels. The Company delivers its medical device modules to OEM companies, such as Cardinal Health/Carefusion, and Roche. It outsources production of its products to manufacturers in Asia. The Company derives revenue from sales of its wireless device products. These products consist of routers, compact flash adapters/modules, universal serial bus (USB) adapters/modules, mini peripheral component interconnect (PCI) modules, PCI Express mini modules and mobile wireless products. It provides optimized wireless products to the medical industry, which has concentrated on using wireless solutions as a way to reduce healthcare costs as a whole.

10 Best Medical Stocks To Watch For 2015: Elan Corporation PLC (ELN)

Elan Corporation, plc (Elan), incorporated in December 1969, is a neuroscience-based biotechnology company. The Company is focused on discovering and developing advanced therapies in neurodegenerative and autoimmune diseases. Elan�� business focuses on neurodegenerative diseases, such as Alzheimer�� disease and Parkinson�� disease; autoimmune diseases, including MS and Crohn�� disease and neo-epitope based targets for treatments across a range of therapeutic indications. Tysabri is a treatment for MS and Crohn�� disease that the Company markets and distributes with Biogen Idec. On September 16, 2011, Elan sold its EDT business to Alkermes, Inc. In November 2011, Elan launched a collaboration with the University of Cambridge, England, the Cambridge-Elan Centre for Research Innovation and Drug Discovery (Cambridge-Elan Centre). On December 21, 2012, the Company completed the demerger of Prothena Corporation plc. In April 2013, it closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.

Tysabri

Tysabri, which is an alpha-4 integrin inhibitor, is a therapy for MS, a neurological disorder involving central nervous system dysfunction among adults. Tysabri is approved in more than 65 countries. Tysabri is approved in the United States as a monotherapy for relapsing forms of MS, for patients who have had an inadequate response to, or are unable to tolerate, an alternative MS therapy. In the European Union, it is approved for relapsing-remitting MS (RRMS) in adult patients who have failed to respond to beta interferon or have rapidly evolving, severe RRMS. As of December 31, 2011, there were approximately 64,400 patients on Tysabri therapy worldwide.

In June 2011, the European Commission (EC) approved the inclusion of the anti-JCV antibody status as an additional factor in stratifying patients at risk for developing PML in the Summary of Product Characteristics��(SmPC) for Tysabri in the European Union. The Company has developed a two-step ! enzyme-linked immunosorbent assay (ELISA), STRATIFY JCV, with Biogen Idec. The assay detects anti-JCV antibodies in the blood of patients, and is commercially available in Europe. In January 2012, the FDA cleared the assay for commercial use in the United States. As of December 31, 2011, over 80,000 tests had been administered using the assay. Tysabri is marketed and distributed by Elan and Biogen Idec. The Company�� research group, Neotope, is focused on creating monoclonal antibodies based on neo-epitope targets for the treatment of a range of therapeutic indications.

Beta Amyloid Immunotherapies (AIP)

Beta amyloid immunotherapy includes the treatment of Alzheimer�� disease by inducing or enhancing the body�� immune response in order to clear toxic species of beta amyloid from the brain. The AIP includes bapineuzumab (intravenous and subcutaneous delivery) and ACC-001, as well as other compounds. Bapineuzumab is an experimental humanized monoclonal antibody delivered intravenously that is being studied as a treatment for mild to moderate Alzheimer�� disease. It is designed to provide antibodies to beta amyloid directly to the patient (passive immunotherapy).

ELND005, an A� Aggregation Inhibitor

The small molecule ELND005 (Scyllo-inositol) is a beta amyloid anti-aggregation agent. Preclinical data suggest that ELND005 may act through the mechanism of preventing and reversing the fibrilisation of beta amyloid (the aggregation of beta amyloid into clumps of insoluble oligomers). ELND005 may have additional applications in psychiatric indications, such as bipolar disorder. In November 2011, the Company entered into a manufacturing agreement for the supply of the active pharmaceutical ingredient for ELND005 with Lonza Group AG.

Neotope Biosciences Limited

Neotope Biosciences Limited (Neotope) is the Company�� wholly owned subsidiary that focuses on the discovery and development of antibodies to neo-epitope related targ! ets for t! he treatment of a range of indications. It includes amyloidosis, diabetes, cancer and macular degeneration. Neotope�� portfolio of targets includes alpha-synuclein for the potential treatment of synucleinopathies, such as Lewy body dementia and Parkinson�� disease, tau for Alzheimer�� disease and other tauopathies. It also has a program for type 2-diabetes.

Onclave Therapeutics Limited

Elan�� wholly owned subsidiary Onclave Therapeutics Limited (Onclave) was formed to develop assets originating from Elan that have application in oncology related diseases. Onclave�� program, NEOD001, which originated from Neotope, is being investigated for the treatment of AL amyloidosis, which is a fatal disease involving abnormal accumulation of amyloid in organs and tissue. During the year ended December 31, 2011, Onclave filed for orphan drug designation of NEOD001. Onclave�� pipeline includes additional compounds with relevance in diverse cancer indications.

The Company competes with Biogen Idec, Bayer Schering Pharma AG, Bayer Schering Pharma, Merck Serono, Pfizer, Teva Neurosciences, Inc., Sanofi-Aventis and Novartis AG.

Advisors' Opinion:

• [By Tim Brugger]

  After confirming an unsolicited takeover bid from privately held investment firm Royalty Pharma in late February, Ireland-based Elan (NYSE: ELN  ) announced today that its board has unanimously rejected the offer.

• [By Russ Krull]

  Finally, Ireland-based biotech Elan (NYSE: ELN  ) issued $850 million of eight-year notes. The money is going to help pay for a royalty stake in some Theravance products. Elan expects the transaction to add to earnings starting in 2014. My Foolish colleagues Sean Williams and Brian Orelli think this might be a better deal for Theravance than for Elan.

• [By Sofia Horta e Costa]

  Bellway Plc (BWY) added 1.4 percent after the homebuilder said reservations in the past four months rose 31 percent as buyers had greater access to mortgages. Elan (ELN) Corp. jumped to a 10-month high in Dublin after Royalty Pharma increased its offer for the Irish drugmaker to as much as $6.7 billion. BT Group increased 3.7 percent as Barclays Plc recommended investors buy shares of the U.K.�� largest fixed-line company.

• [By Tim Brugger]

  Following the denial of an acquisition offer from Royalty Pharma on April 22 equal to $11.25 a share, or less, for all of Elan's (NYSE: ELN  ) outstanding shares, a revised offer from Royalty of $12.50 a share has also been rejected, Elan announced today.

10 Best Medical Stocks To Watch For 2015: EntreMed Inc (ENMD.PH)

EntreMed, Inc. (EntreMed), incorporated in 1991, is a clinical-stage pharmaceutical company. EntreMed's drug candidate is ENMD-2076, an Aurora A and angiogenic kinase inhibitor for the treatment of cancer. ENMD-2076 has completed Phase I studies in patients with advanced solid tumors, multiple myeloma and leukemia and is completing data for a multi-center Phase II study in patients with platinum resistant ovarian cancer. The Company�� other product candidates have includes MKC-1, ENMD-1198 and 2-methoxyestrdiol (2ME2, Panzem) for treatment of rheumatoid arthritis.

ENMD-2076 is a novel orally-active, Aurora A/angiogenic kinase inhibitor with potent activity against Aurora A and multiple tyrosine kinases linked to cancer and inflammatory diseases. ENMD-2076 is relatively selective for the Aurora A isoform in comparison to Aurora B. Aurora kinases are key regulators of the process of mitosis, or cell division, and are often over-expressed in human cancers. E NMD-2076 exerts its effects through multiple mechanisms of action, including anti-proliferative activity and the inhibition of angiogenesis. ENMD-2076 has demonstrated significant, dose-dependent preclinical activity as a single agent, including tumor regression, in multiple xenograft models (such as breast, colon, leukemia), as well as activity towards ex vivo-treated human leukemia patient cells.

10 Best Medical Stocks To Watch For 2015: Revolutions Medical Corp (RMCP)

Revolutions Medical Corporation (Revolutions Medical), incorporated on August 16, 1996, is principally engaged in the designing, developing and commercializing of retractable vacuum safety needle devices. The Company is engaged in the development of technology which can segment and reference MRI images. The Company also has developed a suite of MRI software tools; RevColor, Rev3D, RevDisplay, and RevScan. MRI (Magnetic Resonance Imaging) is used imaging system that safely creates many different and detailed views of selected portions of the internal anatomy.

The RevVac safety syringe uses vacuum technology to retract the needle into the plunger immediately after use. The syringe cannot be reused once the vacuum is activated. When an MRI is taken, the black and white images are sent to a picture archiving and communication system (PACS), which displays the images for a radiologist to view. By using high speed Internet, these images can be securely sent to the Company�� secure Website, after a secure account is opened. This process is called teleradiology.

The Company competes with Med-Design Corporation, New Medical Technologies, Retractable Technologies, Inc., Unilife, Inc., Specialized Health Products International, BD and Covidien Ltd, Terumo Medical Corp. and B. Braun internationally.

10 Best Medical Stocks To Watch For 2015: Dyadic International Inc (DYAI)

Dyadic International, Inc. (Dyadic), incorporated in September 2002, is a holding company. The Company is a global biotechnology company. The Company has operations at the United States and the Netherlands. Dyadic uses its technologies to conduct research and development (R&D) and commercial activities for the discovery, development, manufacture and sale of enzymes and proteins for the bioenergy, industrial enzyme, and biopharmaceutical industries. The Company derives all of its revenues from the licensing of its technologies, the sale of its enzymes and conducting research and development (R&D) activities for third parties. The Company operates in two segments: the United States operations and The Netherlands operations. The United States segment includes a subsidiary in Poland.

The United States operating segment is a developer, manufacturer and distributor of enzyme products, proteins, peptides and other bio-molecules derived from genes and a collaborative licensor of enabling technologies for the development and manufacturing of biological products and use in R&D. The Netherlands operating segment is also a researcher and developer of enzyme products, proteins, peptides and other bio-molecules derived from genes and, to date, has mainly invested in R&D activities.

Dyadic�� R&D activities focus on its fungal strains and associated technologies. Dyadic uses its Trichoderma and C1 fungal strains in the production of its industrial enzymes. Dyadic manufactures and sells liquid and dry enzyme products to global customers for use within the animal feed, pulp and paper, starch and alcohol, food and brewing, textiles, and biofuels industries.

Dyadic also utilizes a technology platform based on its patented and C1 fungus (the C1 Platform Technology), which enables the development and manufacture of proteins and enzymes for diverse market opportunities. The C1 Platform Technology can also be used to screen for the discovery of novel genes and proteins. The C1 Platf! orm Technology also has the potential of developing and producing other biological products such as antibodies, vaccines, proteins and polypeptides for the biopharmaceutical industry.

10 Best Medical Stocks To Watch For 2015: Sunshine Heart Inc (SSH)

Sunshine Heart, Inc., incorporated on August 22, 2002, is an early-stage medical device company focused on developing, manufacturing and commercializing its C-Pulse Heart Assist System for treatment of Class III and ambulatory Class IV heart failure. The C-Pulse Heart Assist System utilizes the scientific principles of intra-aortic balloon counter-pulsation applied in an extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries. As of December 31, 2011, the Company was in the process of obtaining regulatory approvals necessary to sell its product.

The Company has developed tools to allow the C-Pulse to be implanted through a small pacemaker-like incision between the patient�� ribs and sternum rather than a sternotomy. Patients implanted through its minimally invasive procedure require a hospital stay of four to seven days in connection with implantation of the C-Pulse System, after which they return home. During the year ended December 31, 2011, the Company completed enrollment and implantation of 20 patients in the North American feasibility phase of its trial. In April 2011, the Food and Drug Administration (FDA) approved an expansion protocol to allow the Company to implant up to 20 additional patients and add two additional centers to its feasibility study.

The Company competes with Thoratec Corporation, HeartWare International Inc., CircuLite, Inc., CardioKinetix, Inc., AbioMed, Inc., Jarvik Heart, Inc., MicroMed Technology, Inc., SynCardia Systems, Inc., Terumo Heart, Inc., WorldHeart Corporation in the United States and Europe, and Berlin Heart GmbH in Europe.

Advisors' Opinion:

• [By John Udovich]

  Small cap heart stocks Sunshine Heart Inc (NASDAQ: SSH), Abiomed, Inc (NASDAQ: ABMD) and AtriCure Inc (NASDAQ: ATRC) each find different ways go to the heart of the problem for cardiac�patients and have all been good performers for investors this year. After all and according to statistics collected by the CDC, heart disease is the leading cause of death for both men and women as about 600,000 people die of heart disease in the United States every year���accounting�for 1 in every 4 deaths. Moreover, roughly 715,000 Americans have a heart attack every year and�ff these, 525,000 are a first heart attack and 190,000 happen to people who have already had one. In other words, there is a big market for the following small cap heart stocks to address:

10 Best Medical Stocks To Watch For 2015: Uroplasty Inc (UPI)

Uroplasty, Inc., incorporated in January 1992, is a medical device company that develops, manufactures and markets products for the treatment of voiding dysfunctions. The Company�� primary focus is on two products: the Urgent PC Neuromodulation system and Macroplastique Implants. The Urgent PC system is a United States Food and Drug Administration (FDA)-approved minimally invasive, office-based neuromodulation therapy for the treatment of overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency, and urge incontinence; and Macroplastique Implants a urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency (ISD). Outside of the United States, the Company�� Urgent PC is also approved for treatment of fecal incontinence, and Macroplastique is also approved for treatment of male stress incontinence and vesicoureteral reflux.

Urgent PC Neuromodulation System

Using a small-gauge needle electrode inserted above the ankle, the Urgent PC System delivers electrical impulses to the tibial nerve that travel to the sacral nerve plexus, a control center for pelvic floor and bladder function. Components of the Urgent PC system include a hair-width needle electrode, a lead set, and an external, handheld, battery-powered stimulator. For each 30-minute, office-based therapy session, the physician or other qualified healthcare provider inserts the needle electrode in the patient�� lower leg and connects the electrode to the stimulator. Typically, a patient undergoes 12 consecutive weekly treatment sessions, with follow-up maintenance treatments as required to sustain the therapeutic effect. The Company has received regulatory clearances for sale of the Urgent PC system in the United States, Canada and Europe. It also has launched its second generation Urgent PC system.

Macroplastique

Macroplastique is designed to restore the patient�� urinary contine! nce immediately following treatment. Macroplastique is a soft-textured, permanent implant injected, under endoscopic visualization, around the urethra distal to the bladder neck. It is a composition of heat vulcanized, solid, soft, irregularly shaped polydimethylsiloxane (solid silicone elastomer) implants suspended in a biocompatible excretable carrier gel. Macroplastique does not degrade, is not absorbed into surrounding tissues and does not migrate from the implant site. The Company has sold Macroplastique for several urological indications in over 40 countries outside the United States.

Other Uroplasty Products

The Company markets outside of the United States minimally invasive products to address fecal incontinence. Its PTQ Implants offer minimally invasive, soft-textured permanent implant for treatment of fecal incontinence. The PTQ Implants are implanted circumferentially into the submucosa of the anal canal, creating a bulking and supportive effect similar to that of Macroplastique injection for the treatment of stress urinary incontinence. The PTQ is Conformite Europeenne (CE) marked and is sold outside the United States in various international markets. The Urgent PC is also CE marked and sold outside of the United States for the treatment of fecal incontinence. In addition to urological applications, the Company markets its tissue bulking material outside the United States for otolaryngology vocal cord rehabilitation applications under the trade name VOX Implants. In the Netherlands and the United Kingdom only, the Company distributes certain wound care products in accordance with a distributor agreement.

The Company competes with Pfizer Inc., Johnson and Johnson, Novartis, Allergan, GlaxoSmithKline, Carbon Medical Technologies, BioForm, Inc., Q-Med AB and Contura.

Advisors' Opinion:

• [By Lisa Levin]

  Uroplasty (NASDAQ: UPI) shares reached a new 52-week high of $5.22 after the company reported strong Q3 results.

  Juniper Networks (NYSE: JNPR) shares gained 8.23% to touch a new 52-week high of $28.15 after the company reported better-than-expected fourth-quarter results. Barclays upgraded the stock from Equalweight to Overweight and lifted the price target from $29.00 to $34.00.

10 Best Medical Stocks To Watch For 2015: Prima BioMed Ltd (PBMD.W)

Prima BioMed Ltd is a biotechnology company is engaged in the development and commercialization of medical therapies with a focus on oncology. Its product candidates in development include Cvac, an autologous dendritic cell vaccine for ovarian cancer, monoclonal antibodies for multiple tumour types, and an oral formulation for the human papilloma virus (HPV), vaccine. Its product candidate Cvac is a dendritic cell therapy, for which it is conducting a Phase IIb trial for the treatment of ovarian cancer. Cvac is designed to target the tumour antigen mucin-1, which is expressed at high levels on different tumour types. It also has two preclinical product development programs. In May 2011, Prima BioMed GmbH, a 100 % owned subsidiary of Prima BioMed Ltd, was incorporated in Germany. In May 2011, Prima BioMed Middle East FZLLC, a 100 % owned subsidiary of Prima BioMed Ltd, was incorporated in the United Arab Emirates.

10 Best Medical Stocks To Watch For 2015: InVivo Therapeutics Holdings Corp (NVIV)

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., incorporated on April 2, 2003, is a development-stage company. The Company is developing and commercializing technologies for the treatment of spinal cord injuries. The Company develops biopolymer scaffolding devices for the treatment of spinal cord injuries. The biopolymer devices are designed to protect the damaged spinal cord from further secondary injury and promote neuroplasticity, a process where functional recovery can occur through the rerouting of signalling pathways to the spared healthy tissue.

The Company�� biopolymer-based devices are surgically implanted or injected into the lesion created during traumatic injury, or the primary injury. Additional applications of its platform technologies include the treatment for, spinal cord injury following tumor removal, peripheral nerve damage, and postsurgical treatment of any transected nerve. Its biocompatible scaffolding device for the treatment of acute spinal cord injury, is regulated as a Class III medical device by the Food and Drug Administration (FDA). The Company's biocompatible hydrogel is used for the local release of methylprednisolone to treat acute spinal cord injuries and the biocompatible polymer scaffolding device seeded with autologous human neural stem cells.

The Company�� porous biopolymer scaffold consists of polylactic-co-glycolic acid (PLGA) and-polylysine. PLGA is a biodegradable and biocompatible polymer, which is used for applications, such as surgical sutures (Dolphin sutures and Ethicon sutures), drug delivery (Lupron Depot and Sandostatin LAR Depot), and tissue engineering (Dermagraft). The PLGA-polylysine biopolymer scaffolding device is biocompatible and biodegradable and degrades naturally inside the body without requiring subsequent removal.

The Company focuses to develop an injectable hydrogel designed to counteract the inflammatory environment that results during a secondary injury from a closed-wound spi! nal cord injury where further cell death occurs. It focuses to counteract the pathophysiology of spinal cord injury by replacing lost cells of the spinal cord and activating endogenous regenerative processes, such as the formation of new synapses and axonal sprouting based on molecules the stem cells produce.

Advisors' Opinion:

• [By Bryan Murphy]

  I came close to pointing this out yesterday, but didn't pull the trigger. Though delaying didn't cost you or me more than a few cents, I don't want to tarry any longer... Invivo Therapeutics Holdings Corp. (OTCBB:NVIV) is a buy.

10 Best Medical Stocks To Watch For 2015: Autoimmune Inc (AIMM)

AutoImmune Inc., incorporated in September 1988, is a healthcare company. The Company�� products are based on the principles of mucosal tolerance. The Company�� product is sold by Colloral LLC, the Company�� joint venture with Deseret, under the brand name Colloral, The Collagen Solution and Vital 3, and by Futurebiotics LLC under the brand name Vital 3. The other products which are in the development stage include MBP8298 (dirucotide), Oral Copaxone and AI 401.

The Company completed ten human clinical trials involving over 1,900 patients to investigate the use of Colloral as a pharmaceutical for treating symptoms of rheumatoid arthritis. The Company holds a joint venture with Deseret by forming Colloral LLC to manufacture market and sell Colloral as a dietary supplement. Colloral LLC holds a distributing agreement with Futurebiotics LLC for Colloral. Futurebiotics LLC markets the product under the brand name Vital 3. Colloral LLC also markets the product under the Vital 3 brand through The Shopping Channel of Canada via on air segments and their Website.

The Company�� other products in the development stage include MBP8298 (dirucotide) for multiple sclerosis, which is in Phase III trials for secondary progressive multiple sclerosis; Oral Copaxone is in the research stage for multiple sclerosis, and AI 401 is in Phase III trials for Type 1 diabetes. The development of MBP8298 (dirucotide) is conducted by BioMS Medical Corporation (BioMS). In August 2000, BioMS tested patients in a Phase II/III (MAESTRO-01) clinical trial of its MBP8298 treatment for secondary progressive multiple sclerosis. It was conducted at 47 sites across Canada and Europe. In November 2006, BioMS enrolled in a Phase II clinical trial (MINDSET-01) of MBP8298 for treatment of relapsing remitting multiple sclerosis. It enrolled 218 patients at 24 sites in six countries for a 15 month trial.

The Company collaborated with Eli Lilly, which supports clinical testing of orally administered a! utoimmune-mediated (Type 1) diabetes product, AI 401. Eli Lilly completed three different Phase II clinical trials to demonstrate human proof of principle for AI 401. The United States study was a one-year, double-blind, placebo-controlled trial with more than 200 patients, designed to measure immunological changes, preservation of pancreatic function and time to insulin dependence. Its second Phase II trial, involving approximately 150 patients, was conducted in France. The third trial was conducted in Italy with approximately 80 patients. In addition, Eli Lilly provided AI 401 for the Diabetes Prevention Trial (DPT-1) conducted by the National Institutes of Health (NIH). During the year ended December 31, 2008, the clinical trial of intranasal insulin to delay or prevent the clinical onset of Type I diabetes, called the Diabetes Prediction and Prevention Project was conducted in Finland. As of January 1, 2009, 115 had been enrolled in this trial.

10 Best Medical Stocks To Watch For 2015: Myriad Genetics Inc (MYGN.O)

Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests. It performs all of its molecular diagnostic testing and analysis in its own reference laboratories. These technologies include the cornerstone technologies of biomarker discovery, high-throughput deoxyribo nucleuc acid (DNA) sequencing, ribo nucleic acid (RNA) expression and multiplex protein analysis. The Company uses this information to guide the development of new molecular diagnostic tests that are designed to assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to ensure optimal treatment (personalized medicine), or assess a patient's risk of disease progression and disease recurrence (prognostic medicine).

As of June 30, 2012, the Company h ad launched nine commercial molecular diagnostic tests. The Company markets these tests through its own approximate 385-person sales force in the United States. The Company also markets its BRACAnalysis, COLARIS, and COLARIS AP tests through its own European sales force and have entered into marketing collaborations with other organizations in selected Latin American, European and Asian countries. The Company also generates revenue by providing companion diagnostic services to the pharmaceutical, and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology.

Molecular Diagnostic Tests

The Company's molecular diagnostic tests are designed to analyze genes, their mutations, expression levels and proteins to assess an individual's risk for developing disease later in life, determine a patient's likelihood of responding to a particular drug, assess a patient's risk of disease progression and disease recu rrence and measure a patient's exposure to drug therapy to! e! nsure optimal dosing and reduced drug toxicity. The Company's BRACAnalysis test is a analysis of the BRCA1 and BRCA2 genes for assessing a woman's risk of developing hereditary breast and ovarian cancer. BRACAnalysis accounted for 81.7% of the Company's total revenue during the fiscal year ended June 30, 2012. Its The Company's COLARIS test is an analysis of the MLH1, MSH2, MSH6 and PMS2 genes for assessing a person's risk of developing colorectal cancer or uterine cancer.

The Company's COLARIS AP test detects mutations in the APC and MYH genes, which cause a colon polyp-forming syndrome known as Familial Adenomatous Polyposis (FAP), a more common variation of the syndrome known as attenuated FAP, and the MYH-associated polyposis signature (MAP). The Company's MELARIS test analyzes mutations in the p16 gene to determine genetic susceptibility to malignant melanoma. The Company's OnDose test is a nanoparticle immunoassay that is designed to assist oncologists in optimizing 5-FU (fluorouracil) anti-cancer drug therapy in colon cancer patients on an individualized basis. The Company's PANEXIA test is a comprehensive analysis of the PALB2 and BRCA2 genes for assessing a person's risk of developing pancreatic cancer later in life. The Company's PREZEON test is an immunohistochemistry test that analyzes the PTEN gene and assesses loss of PTEN function in many cancer types.

The Company's Prolaris test is a 46-gene molecular diagnostic assay that assesses whether a patient is likely to have a slow growing, indolent form of prostate cancer that can be safely monitored through active surveillance, or a more aggressive form of the disease that would warrant aggressive intervention, such as a radical prostatectomy or radiation therapy. The Company's TheraGuide 5-FU test analyzes mutations in the DPYD gene and variations in the TYMS gene to assess patient risk of toxicity to 5-FU (fluorouracil) anti-cancer drug therapy.

< p>Companion Diagnostic Services and Other Revenue

! Throug! h Myriad RBM Inc., the Company provides biomarker discovery and companion diagnostic services to the pharmaceutical, biotechnology, and medical researches industries utilizing its multiplexed immunoassay technology. The Company's technology enables the Company to screen large sets of clinical samples from both diseased and non-diseased populations against the Company's menu of biomarkers. The Company's companion diagnostic services consist of Multi-Analyte Profile (MAP), Multiplexed Immunoassay Kits and TruCulture.

The Company has compiled a library of over 550 individual human and rodent immunoassays for use in its multi-analyte profile (MAP) testing services. The Company has also developed RodentMAP, a panel for use in pre-clinical animal studies and OncologyMAP, which measures cancer-related proteins to assists researchers accelerate the pace of discovery, validation and translation of cancer biomarkers for early detection, patient stratification and therapeu tic monitoring. The Company has developed multiplexed immunoassay kits that enable its customers to leverage its technology services with their in-house capabilities. The Company's internally developed multiplexed immunoassay kits include all of the components necessary for a customer to perform a test on their own Luminex instrument. TruCulture is a simple, self-contained whole blood culture that can be deployed to clinical sites around the world for acquiring cell culture data without specialized facilities or training.

10 Best Medical Stocks To Watch For 2015: Applied Nanotech Holdings Inc (APNT)

Applied Nanotech Holdings, Inc., incorporated on May 22, 1989, is engaged in nanotechnology research and development business. The Company's nanotechnology research involves performing contract research and development services for others to develop products and materials for new applications, and then leveraging this research by applying it to other similar applications in other industries. The Company also develops intellectual property (IP) around its products and technologies. The Company develops five technology platforms: nanosensor technology; nanocomposites, based on carbon nanotube composites; thermal management materials; nanoelectronics applications, and electron emission activities, primarily in the display area. The Company's electron emission IP is divided into display activities and non-display activities. Applied Nanotech Holdings, Inc. is the parent company. Applied Nanotech, Inc. (ANI) is a subsidiary of ANHI. During the year ended December 31, 2012, the Company formed EZDiagnostix, Inc., (EZDX).

Sensors

The Company develops sensors based on ion mobility sensor technology and differential mobility spectroscopy. The Company is involved in projects to develop Mercaptan and Methane sensors for uses in the natural gas industry. The Company is also applying this technology to other applications, including agricultural pathology, wound care, and breath analysis. The Company develops hydrogen sensor for use in the measurement of hydrogen in power transformer products. The Company develops carbon monoxide sensor that can last for 10,000 hours on a single battery. The Company's carbon nanotube technology is for use in biosensors. Sensors based on carbon nanotubes or other nanomaterials can be used to detect chemical, organic, or biological warfare agents, as well as explosives, hydrogen, ammonia and numerous other chemicals.

Nanocomposites

The Company is in the advanced stages of development of nanomaterials using carbon nanotube (CNT) and! other composites. Epoxies are used in industries with worldwide markets, with applications, including adhesives, paints, coatings, and composites. In addition to epoxy resins, the Company develops other types of resins, including polyesters and vinyl esters. Vinyl esters are used in a variety of industrial applications, including storage tanks, piping, and construction. The Company develops a process for coating nylon pellets with CNTs to improves electrical conductivity. Nylon 6 with improved electrical conductivity can be used for its anti-static qualities, electrostatic discharge, and electromagnetic/RF shielding.

Thermal Management

The Company markets thermal management material called CarbAl. CarbAl provides a passive thermal management solution for temperature control issues that plague electronics manufacturers. CarbAl is a carbon based metal nanocomposite comprised of 80% carbonaceous matrix and a dispersed metal component of 20% aluminum. The Company also develops a simplified version of CarbAl based on graphite.

Conductive Inks

The Company develops aluminum and silver inks and pastes that is ideal for use in the production of solar cells. The Company also develops aluminum paste that can be used in current solar cell production.

The Company competes with Zyvex Performance Materials, GSI Creos, Amroy Europe, Ltd., DuPont and Ferro

Advisors' Opinion:

• [By Anuchit Nguyen]

  India�� S&P BSE Sensex rose, holding at a three-year high, amid better-than-estimated corporate earnings. Engineering company Larsen & Toubro Ltd. (LT) rallied to a three-month high and Asian Paints Ltd. (APNT) surged about 6 percent after reporting profit that beat forecasts.

Top 5 Beverage Companies To Own In Right Now

The Financial Times recently reported that cola giant The Coca-Cola Company (KO) will launch smaller and slimmer versions of its Coke, Diet Coke and Coke Zero brands of soft drink cans in U.K. later this month.

Coca-Cola will launch a 250 ml can, which will contain 105 calories as compared to 139 calories in the larger 330 ml can. The slimmer cans are expected to be priced at the same rate per 100 ml as its larger counterpart.

Beverage giants are witnessing a decline in the sales of carbonated soft drinks (CSD), especially the colas, due to rising health consciousness and increasing public and governmental concerns regarding obesity and other co-morbidities.

To reinvigorate the sales of its sparkling beverages, like Coke and Fanta, The Coca-Cola Company is offering more choices to its customers in package sizes, sweeteners and beverages (including more low- and no-calorie selections). The new slim cans are part of this ongoing plan.

Other beverage companies are also gearing up to cater to the emerging trend. PepsiCo, Inc.�� (PEP) low-calorie cola, Pepsi Next, which contains 60% less sugar, achieved nearly $100 million in retail sales in less than 12 months in the market. PepsiCo is now making evolutionary natural sweeteners and flavorings aimed at reducing calories to re-vitalize declining sales of its colas. The food and beverage giant also aims to grow its nutrition brands like Quaker, Tropicana and Gatorade.

Top 5 Beverage Companies To Own In Right Now: Central European Distribution Corp (CEDCQ.PK)

Central European Distribution Corporation (CEDC), incorporated on September 4, 1997, operates primarily in the alcohol beverage industry. CEDC is a producer of vodka and is Central and Eastern Europe�� integrated spirit beverages business. During the year ended December 31, 2011, as measured by total volume, the Company produced and distributed approximately 33.2 million nine-liter cases . The Company�� business primarily involves the production and sale of its own spirit brands (principally vodka), and the importation on a basis of a range of spirits, wines and beers. Its primary operations are conducted in Poland and Russia. In addition the Company also has operations in Hungary and Ukraine. CEDC has six manufacturing facilities located in Poland and Russia. On February 7, 2011, the Company completed purchasing of the remaining stake of the Whitehall Group.

CEDC is an importer of spirits, wines and beers in Poland, Russia and Hungary. The Company mai ntains import contracts for a number of internationally recognized brands, including Jim Beam Bourbon, Campari, Jagermeister, Remy Martin Cognac, Corona, Budweiser (Budvar), E&J Gallo wines, Carlo Rossi wines, Sutter Home wines, Metaxa Brandy, Sierra Tequila, Teacher�� Whisky, Cinzano, Old Smuggler, Grant�� Whisky and Concha y Toro wines. In addition to its operations in Poland, Russia, and Hungary the Company has Ukraine and distribution agreements for its vodka brands in a number of key export markets including the United Kingdom, Ukraine, the Baltics and the CIS for Green Mark, Zhuravli, Parliament and Zubrowka, the United States, Japan, the United Kingdom, France for Zubrowka and many other Western European countries. In 2011, exports represented 11% of its sales by value.

Poland

In Poland, CEDC is the vodka producers with a brand portfolio that includes Absolwent, Zubrowka, Zubrowka Biala, Bols, Palace and Soplica brands, each of which it p roduces at its Polish distilleries. It produces and sells ! vo! dkas primarily in three vodka sectors: premium, mainstream, and economy. The Company owns two production sites in Poland: one in Oborniki and one in Bialystok. In the Oborniki distillery, it produces the Bols and Soplica vodka brands, among other spirit brands. In Bialystok it produces Absolwent and Zubrowka. Zubrowka is also exported out of Poland to many markets around the world, including the United States, England, Japan and also France. In addition to the Absolwent and Zubrowka brands, in Bialystok it produces the Zubrowka Biala brand. The Company has rights to import and distribute approximately 70 brands of spirits, wine and beer into Poland. It also provides marketing support to the suppliers. During 2011, the Company sold approximately 10.7 million nine-liter cases of vodka, wine and spirits through its Polish business during 2011 including both its own produced vodka brands as well as its exclusive agency import brands. During 2011, the Company sold approximately 1 91 thousand nine-liter cases of Zubrowka outside of Poland. During 2011, the Company�� Polish operations accounted for 26.3% of its revenue.

Russia

CEDC produces Green Mark in Russia and the sub-premium vodkas in Russia, Parliament and Zhuravli. During 2011 the Company introduced new brands to the Russian market Talka, Sotka and Silver Blend. The Company also produces Yamskaya, the economy vodka in Russia, and premixed alcohol drinks, or long drinks. The Company also owns Whitehall, which holds the exclusive rights to the import of such leading premium wine and spirit brands as Concha y Toro, Paul Masson, Robert Mondavi, DeKuyper, Jose Cuervo and Label 5. In addition to these import activities, Whitehall has distribution centers in Moscow, Saint Petersburg, and Rostov as well as a wine and spirits retail network located in Moscow. During 2011, the Company�� Russian operations accounted for 70.2% of its revenue. During 2011,the Company produced a nd sold approximately 16.6 million nine-liter cases of! vodka! t! hrough ! its Russian business in the main vodka segments in Russia: premium, sub-premium, mainstream, economy and cheap. In addition it produced and sold approximately 2.8 million nine-liter cases of long drinks.

Hungary

The Company sells Royal Vodka in Hungary through its Bols Hungary subsidiary. The imported brands to Hungary include Bols Vodka, Zubrowka, Royal Vodka, Campari, Cinzano, Jaegermeister, Bols Liqueurs, Cointreau, Carolans, Galliano, Irish Mist, Jose Cuervo, Calvados Boulard, Remy Martin, Metaxa, St Remy, Grant��, Glenfiddich, Tullamore Dew and Old Smuggler.

Top 5 Beverage Companies To Own In Right Now: WhiteWave Foods Co (WWAV.N)

WWF Operating Company, incorporated on March 14, 1988, is a consumer packaged food and beverage company. The Company manufactures, markets, distributes, and sells plant-based foods and beverages, coffee creamers and beverages, and dairy products throughout North America and Europe. The Company operates in two segments: North America and Europe. The North America segment offers products in the plant-based foods and beverages, coffee creamers and beverages, and dairy product categories throughout North America. Europe segment offers plant-based food and beverage products throughout Europe. The Company is a wholly owned subsidiary of Dean Foods Company (Dean Foods).

The Company�� brands distributed in North America include Silk plant-based foods and beverages, International Delight and LAND O LAKES coffee creamers and beverages, and Horizon Organic dairy products, while its European brands of plant-based foods and beverages include Alpro and Provamel. The Co mpany sell its products to a variety of customers, including grocery stores, mass merchandisers, club stores, and convenience stores, as well as various away-from-home channels, including restaurants and foodservice outlets, across North America and Europe. The Company sells its products in North America and Europe primarily through its direct sales force and independent brokers. The Company utilizes five manufacturing plants, two distribution centers, and three co-packers across the United States. Additionally, it has four plants across Europe in the United Kingdom, Belgium, France, and the Netherlands, each supported by an integrated supply chain.

5 Best Industrial Conglomerate Stocks To Own Right Now: Fomento Economico Mexicano SAB de CV (FMX)

Fomento Economico Mexicano, S.A.B. de C.V. (FEMSA), incorporated on May 30, 1936, is a holding company. The Company conducts its operations through principal holding companies, each of which it refers to as a principal sub-holding company. These companies are Coca-Cola FEMSA, S.A.B. de C.V. (Coca-Cola FEMSA), which engages in the production, distribution and marketing of soft drinks, and FEMSA Comercio, S.A. de C.V. (FEMSA Comercio), which operates convenience stores. The Company�� convenience store chain OXXO operated a total of 7,492 stores as of March 31, 2010. Compania Internacional de Bebidas, S.A. de C.V. (CIBSA) owns a 53.7% interest in Coca-Cola FEMSA. On April 30, 2010, FEMSA announced the closing of the transaction, pursuant to which FEMSA agreed to exchange 100% of its beer operations conducted by FEMSA Cerveza for a 20% economic interest in the Heineken Group. In February 2009, Coca-Cola FEMSA acquired with The Coca-Cola Company the Brisa bottled water business in Colombia from Bavaria, a subsidiary of SABMiller. Coca-Cola FEMSA acquired the production assets and the rights to distribute in the territory, and The Coca-Cola Company obtained the Brisa brand.

Coca-Cola FEMSA, S.A.B. de C.V.

Coca-Cola FEMSA is a bottler of Coca-Cola trademark beverages. Coca-Cola FEMSA operates in various territories, including Mexico, a substantial portion of central Mexico (including Mexico City and the states of Michoacan and Guanajuato) and southeast Mexico (including the Gulf region); Central America, including Guatemala (Guatemala City and surrounding areas), Nicaragua (nationwide), Costa Rica (nationwide) and Panama (nationwide); Colombia; Venezuela; Argentina, including Buenos Aires and surrounding areas, and Brazil, including the area of greater Sao Paulo, Campinas, Santos, the state of Mato Grosso do Sul, the state of Minas Gerais and part of the state of Goias.

Coca-Cola FEMSA produces, markets and distributes Coca-Cola trademark beverages, own brands and b! rands licensed from the Company. The Coca-Cola trademark beverages include sparkling beverages (colas and flavored sparkling beverages), water, and still beverages (including juice drinks, ready-to-drink teas and isotonics). Out of the more than 100 brands and line extensions of beverages sold and distributed by Coca-Cola FEMSA, its most important brand, Coca-Cola, together with its line extensions, Coca-Cola light, Coca-Cola Zero and Coca-Cola light caffeine free, accounted for 61.4% of total sales volume during the year ended December 31, 2009. Coca-Cola FEMSA�� next largest brands, Ciel (a water brand from Mexico), Fanta (and its line extensions), Sprite (and its line extensions), ValleFrut and Hit, accounted for 10.5%, 5.8%, 2.6%, 1.5% and 1.3%, respectively, of total sales volume in 2009. Coca-Cola FEMSA uses the term line extensions to refer to the different flavors in which it offers its brands.

Coca-Cola FEMSA produces, markets and distributes Coca-Cola trademark beverages in each of its territories in containers authorized by The Coca-Cola Company, which consist of a variety of returnable and non-returnable presentations in the form of glass bottles, cans and plastic bottles made of polyethylene terephtalate (PET). Coca-Cola FEMSA uses the term presentation to refer to the packaging unit in which it sells its products. Presentation sizes for its Coca-Cola trademark beverages range from a 6.5-ounce personal size to a 3-liter multiple serving size. For all of its products excluding water, Coca-Cola FEMSA considers a multiple serving size as equal toor larger than one liter. In addition, it sells some Coca-Cola trademark beverage syrups in containers designed for soda fountain use, which it refers to as fountain. It also sells bottled water products in bulk sizes, which refers to presentations equal to or larger than five liters, which have a much lower average price per unit case than its other beverage products.

In Mexico, Coca-Cola FEMSA�� product portfolio consis! ts of Coc! a-Cola trademark beverages, and includes Mundet trademark beverages licensed from FEMSA in some Mexican territories. Coca-Cola FEMSA�� product sales in Latincentro consist predominantly of Coca-Cola trademark beverages. Per capita consumption of its sparkling beverages products in Colombia and Central America was 92 and 146 eight-ounce servings, respectively, in 2009. Its product portfolio in Venezuela consists of Coca-Cola trademark beverages. Sparkling beverages per capita consumption of its products in Venezuela was 174 eight-ounce servings during 2009. Coca-Cola FEMSA�� product portfolio in Mercosur consists mainly of Coca-Cola trademark beverages, and the Kaiser beer brand in Brazil, which Coca-Cola FEMSA sells and distributes on behalf of FEMSA Cerveza. Sparkling beverages per capita consumption of its products in Brazil and Argentina was 214 and 359 eight-ounce servings, respectively, in 2009.

The Company competes with Pepsi Beverage Company, Grupo Embotelladores Unidos, S.A.B. de C.V., Grupo Jumex, Groupe Danone, Cadbury Schweppes, Big Cola, Consorcio AGA, S.A. de C.V., Postobon, Florida Ice and Farm Co. S.A., Cerveceria Nacional, S.A., Pepsi-Cola Venezuela, C.A., AmBev and Quilmes Industrial S.A.

FEMSA Comercio, S.A. de C.V.

FEMSA Comercio operates a chain of convenience stores in Mexico, under the trade name OXXO. OXXO stores are concentrated in the northern part of Mexico, but also have a presence in central Mexico and the Gulf coast. FEMSA Comercio is the largest single customer of FEMSA Cerveza and of the Coca-Cola system in Mexico. During 2009, a typical OXXO store carried 1,954 different store keeping units (SKUs) in 31 main product categories.

The Company competes with 7-Eleven, Super Extra, Super City, Circle-K and AM/PM.

Advisors' Opinion:

• [By Dividends4Life]

  Memberships and Peers: KO is a member of the S&P 500, a Dividend Aristocrat, a member of the Broad Dividend Achievers��Index and a Dividend Champion. The company's peer group includes: Dr. Pepper Snapple Group (DPS) with a 3.2% yield, Pepsico Inc (PEP) with a 2.6% yield and Fomento Economico ADR (FMX) with a 1.7% yield.

Top 5 Beverage Companies To Own In Right Now: Monster Beverage Corp (MNST)

Monster Beverage Corporation, formerly Hansen Natural Corporation, incorporated on April 25, 1990,is a holding company. The Company develops, markets, sells and distributes alternative beverage. The alternative beverage category combines non-carbonated ready-to-drink iced teas, lemonades, juice cocktails, single-serve juices and fruit beverages, ready-to-drink dairy and coffee drinks, energy drinks, sports drinks, and single-serve still water (flavored, unflavored and enhanced) with new age beverages, including sodas that are considered natural, sparkling juices and flavored sparkling beverages. It has two reportable segments, namely Direct Store Delivery (DSD), whose principal products comprise energy drinks, and Warehouse (Warehouse), whose principal products comprise juice-based and soda beverages. The DSD segment develops, markets and sells products primarily through an exclusive distributor network, whereas the Warehouse segment develops, markets and sells products primarily directly to retailers. Corporate and unallocated amounts that do not relate to the DSD or Warehouse segments specifically, have been allocated to Corporate and Unallocated.

During the year ended December 31, 2012, it continued to expand its existing product lines and flavors and further develop its distribution markets. In particular, it continued to focus on developing and marketing beverages that fall within the category generally described as the alternative beverage category. During the year ended December 31, 2012, it introduced a number of new products, including Monster Rehab Tea + Orangeade + Energy, a non-carbonated energy drink with electrolytes, Monster Energy Zero Ultra, a carbonated energy drink which contains zero calories and zero sugar, bermonster Energy Brew, a non-alcoholic energy drink, manufactured using a brewed fermentation process, Hansen�� Coconut Water, in original and tropical flavors, packaged in re-sealable Tetra Prisma boxes, Peace Tea Cranberry, Pink Lemonade and Texas-Style Sweet ! Tea, ready-to-drink iced teas, Monster Cuba-Lima, a carbonated lime flavored non-alcoholic energy drink, Monster Energy Dub Edition Baller�� Blend, a carbonated punch + energy drink and Monster Energy Dub Edition Mad Dog, a carbonated punch + energy drink.

DSD Segment

Monster Energy Drinks offers products under the Monster Energy drink product line: Monster Energy, Lo-Carb Monster Energy, Monster Energy Assault, Monster Khaos, Monster M-80 (named Ripper in certain countries), Monster MIXXD, Monster Energy Absolutely Zero, Monster Energy Import and Import Light, Monster Energy Dub Edition Baller�� Blend, Monster Energy Dub Edition Mad Dog, M3 Monster Energy Super Concentrate energy drinks, bermonster Energy Brew, Monster Energy Zero Ultra and Monster Cuba-Lima.

Java Monster Coffee + Energy Drinks - A line of non-carbonated dairy based coffee + energy drinks. It offers products under the Java Monster product line: Java Monster Kona Blend, Java Monster Loca Moca, Java Monster Mean Bean, Java Monster Vanilla Light, Java Monster Irish Blend and Java Monster Toffee. Monster Energy Extra Strength Nitrous Technology Energy Drinks - A line of carbonated energy drinks containing nitrous oxide. It offer products under the Monster Energy Extra Strength Nitrous Technology product line: Super Dry, Anti Gravity and Black Ice.

-Presso Monster Coffee + Energy Drinks - A line of non-carbonated dairy based coffee + energy drinks. It offers products under the X-Presso Monster coffee + energy drinks product line: X-Presso Monster Hammer and X-Presso Monster Midnite.

Monster Rehab Tea + Energy Drinks - A line of non-carbonated energy drinks with electrolytes. It offers products under the Monster Rehab drink line: Monster Rehab Tea + Lemonade + Energy, Monster Rehab Rojo Tea + Energy, Monster Rehab Green Tea + Energy, Monster Rehab Protean + Energy and Monster Rehab Tea + Orangeade + Energy.

Worx Energy Energy Shots - A line of energy suppleme! nts which! contains zero calories and zero sugar. It offers products under the Worx Energy energy shot product line: Original Formula and Extra Strength.

Peace Tea Iced Teas - A line of ready-to-drink iced teas. It offers products under the Peace Tea product line: green tea, imported Ceylon tea, sweet lemon tea, razzleberry tea, cranberry tea, pink lemonade tea, Texas-style sweet tea and Caddy Shack tea + lemonade.

Warehouse Segment

Hansen�� brand sodas have been a natural soda brand on the West Coast of the United States for more than 30 years and are made with natural flavors. Hansen�� brand sodas, sweetened with cane sugar, and Hansen�� Diet Sodas, sweetened with Splenda no calorie sweetener and Acesulfame-K, contain no preservatives, sodium, caffeine or artificial colorings. It offers sodas under the Hansen�� brand name: Hansen�� Sodas, Hansen�� Diet Sodas and Hansen�� Natural Mixers, as well as Hansen�� Sparkling Waters, in a variety of flavors.

Its Blue Sky products contain no preservatives, artificial sweeteners, caffeine (other than its Blue Sky energy drinks) or artificial coloring and are made with sugar and natural flavors. It offers products under the Blue Sky product line: Blue Sky Natural Soda, Blue Sky Zero Calorie Sodas (sweetened with Truvia brand stevia extract, an all natural sweetener), Blue Sky Premium Sodas, Blue Sky Organic Natural Sodas, Blue Sky Seltzer Waters, Blue Sky Blue Energy drinks, Blue Sky Zero Calorie Blue Energy drinks, Blue Sky Caf Energy drinks and Blue Sky Recover Energy drinks.

Its original Hansen�� energy drinks compete in the functional beverage category, namely, beverages that provide a benefit in addition to simply delivering refreshment. It offers products under the Hansen�� energy drink product line: Hansen�� Natural Energy Pro, Hansen�� Energy Diet Red and Hansen�� Natural Stamina Pro.

Its fruit juice product line includes Hansen�� Natural Apple Juice, Ha! nsen�� ! Natural Grape Juice, White Grape Juice, Pineapple Juice, Apple Grape Juice, Apple Strawberry Juice, Orange Juice, Cranberry Juice, Cranberry-Apple Juice, Cranberry-Grape Juice, Ruby Red Grapefruit Juice, and Organic Apple Juice. In March 2012, it added Hansen�� Natural Apple Orange Pineapple Juice which contains 100% juice as well as 120% of the United States Recommended Daily Allowances (the USRDA) for vitamin C. It also offer Hansen�� Natural Lo-Cal juice cocktails, a line of all natural, low-calorie cocktails in four flavors. The Lo-Cal juice cocktails are sweetened with Truvia sweetener. Hansen�� juice products compete in the shelf-stable juice category.

It offers a number of aseptically packed boxed juice products, including its dual-branded multi-vitamin 100% juice line, which itsell in conjunction with Costco Wholesale Corporation (Costco) through Costco stores. It offers its Hansen�� Natural line of multi-vitamin 100% juices to other customers. These multi-vitamin juices contain eleven essential vitamins and six essential minerals and are available in a variety of flavors. In February 2012, it added Hansen�� Natural Organic Apple Juice, a 100% USDA Certified Organic Apple Juice with 100% of the USRDA for vitamin C.

Its Hansen�� Junior Juice product line is a 100% juice line targeted at toddlers and preschoolers. These juices have added calcium and all flavors contain 100% of the daily recommended allowance of vitamin C. It also offers organic juices as well as Hansen�� Organic Junior Water, a lightly flavored reduced calorie beverage, both of which contain 100% of the daily recommended allowance of vitamin C. In addition, it offers Junior Juice Coconut Water Twist, a line of fruit and coconut water juices containing 100% of the daily recommended allowance of vitamin C.

Its Hubert�� Lemonade is a line of premium ready-to-drink lemonades. Hubert�� Lemonade is sweetened with cane sugar and Truvia sweetener. Hubert�� Lemonade i! s all nat! ural and contains no preservatives, artificial sweeteners, caffeine, or artificial colorings. It offers products under the Hubert�� Lemonade product line: Strawberry Lemonade, Limeade, Mango Lemonade, Honey Lemonade, Raspberry Lemonade and Original Lemonade. It added Cherry Limeade and Blackberry Lemonade flavors to the product line in February 2012 and October 2012, respectively. In July 2012, it introduced 4-count multi-packs of select flavors.

Hubert�� Half & Half is sweetened with cane sugar and Truvia sweetener, and contains no preservatives, artificial sweeteners, or artificial colorings. Its Fruit and Tea Stix product line is an all-natural, low-calorie powder drink mix line, sweetened naturally with Truvia sweetener. Its Angeleno Aguas Frescas is a line of premium ready-to-drink aguas frescas. Angeleno Aguas Frescas are sweetened with cane sugar and real fruit juice and contain no preservatives, artificial sweeteners, caffeine, or artificial colorings. It offers flavors under the Angeleno Aguas Frescas product line: Mango, Melon, Pineapple, Jamaica (Hibiscus) and Tamarindo. Its Hansen�� Natural PRE products include a line of prebiotic and probiotic digestive wellness ready-to-drink beverages and powder drink mixes, containing specially formulated blends by Jarrow Formulas. PRE prebiotic ready-to-drink beverages are sweetened with either cane sugar or stevia. PRE probiotic powder drink mixes are sweetened with cane sugar and stevia. In March 2012, it introduced Hansen�� Natural Coconut Water, a line of premium 100% Coconut Waters available in Pure and Tropical flavors.

The Company competes with TCCC, PepsiCo, Inc. (PepsiCo), The Dr. Pepper Snapple Group, Inc. (the DPS Group), Red Bull Gmbh, Kraft Foods, Inc., GlaxoSmithKline plc, Nestle Beverage Company, Tree Top Inc. (Tree Top), Ocean Spray Cranberries Inc. (Ocean Spray), Red Bull, Rockstar, Full Throttle, No Fear, Amp, Adrenaline Rush, NOS, Venom, Redline, 180, Red Devil, Rip It, Xenergy, 5-Hour Energy ! Shots, Mi! O Energy, Stacker 2, VPX Redline Energy Shots, Red Bull, Rockstar, Burn, V-Energy, Lucozade, Adrenaline Rush, Power Play, Mother, Hell, Shock, Tiger, Boost, Gladiator, TNT, Shark, Hot 6, Nalu, Battery, Bullit, Flash Up, Black, Non-Stop, Bomba, Semtex, Starbucks Frappuccino, Starbucks Double Shot, Starbucks Double Shot Energy Plus Coffee , other Starbucks coffee drinks, Rockstar Roasted, Seattle�� Best, illy issimo coffee, Full Throttle Coffee, Arizona, Lipton, Snapple, Nestea, Xing Tea, Honest Tea, Gold Peak Tea, Fuze Tea, the DPS Group, Cott Corporation and National Beverage Corporation, Jones Soda Co., Crystal Geyser, J.M. Smucker Company, Reeds, Inc., Zevia, Tree Top, Mott��, Martinelli��, Welch��, Ocean Spray, Tropicana, Minute Maid, Langers, Apple , Eve, Seneca, Northland, Juicy Juice, Old Orchard, Calypso, Simply Lemonade, Minute Maid, Cabana, Tropicana, Newman�� Own, Vita Coco, ZICO and O.N.E.

Advisors' Opinion:

• [By Michael Lewis]

  Energy drink maker Monster Beverage (NASDAQ: MNST  ) has successfully transitioned from market champagne to radioactive cocktail. As the 26th�most-shorted stock on the public markets and with an earnings report only a mother could love, the company is getting pummeled on all fronts. Are the complaints overblown, or is the energy drink gold rush coming to an end for this former favorite? Let's take a look at Monster's recent earnings to see if you should buy the dip or jump on the short train.

Top 5 Beverage Companies To Own In Right Now: Molson Coors Brewing Company(TAP)

Molson Coors Brewing Company brews, markets, sells, and distributes beer brands. It sells its products in Canada, under the Coors Light, Molson, Rickard's Red, Carling, Pilsner, Keystone Light, Creemore Springs, and Granville Island brands. The company also brews or distributes products under license from third parties, which include Heineken, Amstel Light, Murphy's, Asahi, Asahi Select, Miller Lite, Miller Genuine Draft, Miller Chill, Milwaukee's Best, Milwaukee's Best Dry, and Foster's. In addition, it imports, distributes, and markets the Corona, Coronita, Negra Modelo, and Pacifico brands, through a joint venture agreement with Grupo Modelo. Further, the company sells various brands in the United States, which include Coors Light, Miller Lite, Coors Banquet, Miller Genuine Draft, MGD 64, Miller Chill, Sparks, Miller High Life, Miller High Life Light, Keystone Light, Icehouse, Mickey's, Milwaukee's Best, Milwaukee's Best Light, Old English 800, Blue Moon, Henry Weinhard 's, George Killian's Irish Red, Leinenkugel's, Peroni Nastro Azzurro, Pilsner Urquell, Grolsch, Coors Non-Alcoholic, and Sharp's. Additionally, it sells various brands in the United Kingdom comprising Carling, C2, Coors Light, Worthington's, White Shield, Caffrey's, Kasteel Cru, and Blue Moon, as well as various regional ale brands. The company also sells the Grolsch brands through a joint venture with Royal Grolsch N.V. and the Cobra brands through a joint venture called Cobra Beer Partnership Ltd.; and distributes brands sold under license, including Corona, Coronita, Negra Modelo, Pacfico, Singha, and Magners Draught Cider. In addition, it markets and sells Zima, Si'hai, Coors Gold, and Coors Extra brands to various international markets. The company was formerly known as Adolph Coors Company and changed its name to Molson Coors Brewing Company as a result of its merger with Molson Inc. in February 2005. Molson Coors Brewing Company was founded in 1873 and is headquartere d in Denver, Colorado.

Advisors' Opinion:

• [By Aimee Duffy]

  Zero waste is not only possible for Wal-Mart, but many other companies in other industries as well. MillerCoors -- the MolsonCoors (NYSE: TAP  ) and SABMiller joint venture -- has four U.S. breweries that are now landfill-free, meaning the company sends zero waste to landfills. It's flagship Golden, Colo., brewery used to send 135 tons of garbage to a landfill every month, but no more!

• [By Brian O'Connell] Micro-brewers aren’t so micro anymore.
  
  The gourmet beer industry is in a quandary these days that will impact the value of industry stocks, such as Boston Beer (NYSE: SAM), Anheuser-Busch InBev (NYSE: BUD), and MolsonCoors (NYSE: TAP), among others. We think Boston Beer, maker of Sam Adams, is in the best position to thrive.
  
  First, let’s wipe the foam way and study a problem for the industry that’s in significant need of a solution.
  
  The brewery industry has unleashed an army of lobbyists upon Washington, DC, to curry favor, twist some arms (and yes, bend some elbows) to convince Congress to reduce tax burdens micro-brewers consider heavy and onerous. These taxes are a bottom line killer in a combative industry.
  
  Companies such as Boston Beer and Anheuser Busch may have a point on high excise taxes. No longer are North America and Europe no-brainers for beer companies. Growth has stagnated in the so-called “old continents” and breweries are looking to new, emerging market opportunities such as China, India, and increasingly, Africa.
  
  But the entire industry has the dry heaves over a declining market, with older Baby Boomers giving up their wicked ways and their Millennial kids opting for that raspberry cake martini over a nice pint of lager.
  
  That’s where the lobbying campaign comes in, with 2012 a banner year for micro-brewery lobbying efforts, and 2013 should follow suit. In fact, lobbying ranks were significantly swelled as the big micro-brewers put the full-court press on Congress to alleviate what industry executives view as exorbitantly higher excise taxes.
  
  This summer, the US Brewers Association launched a huge lobbying effort that targeted 90 US Senators and 250 members of the House of Representatives, with face-to-face meetings on tap with 250 brewery executives.
  
  Under particular lobbying pressure is House Ways and Means Committee Chairman Dave Camp, a Michigan Republica
• [By Lauren Pollock]

  Molson Coors Brewing Co.'s(TAP) third-quarter earnings fell 39% as the beer company’s results were hurt by a write-down tied to two European brands and revenue weakened slightly. Results were mixed as the bottom line beat views and the top line missed. Shares edged up 1.8% to $55 in light premarket trading.

• [By Jonas Elmerraji]

  Molson Coors Brewing (TAP) operates in a different corner of the alcoholic beverage business: beer. The $9 billion brewer is one of the biggest in the world, with brands like Molson and Coors as well as Blue Moon, Keystone and Miller Lite (the latter through a joint venture with SABMiller (SBMRY: Pink Sheets) here in the U.S.).

  Molson Coors is engaged in a battle of the big boys – as the second largest brewer in Canada and the U.S., the firm primarily competes against top-rival Anheuser Busch Inbev (BUD) for market share. Like BEAM with its small barrel bourbon line, TAP has poured resources into the craft beer segment, the fastest-growing area in the alcoholic beverage space. While that's not likely to materially change its business, it should provide a welcome margin boost.

  Beer sales tend to ebb and flow with the broad economy. In 2013, with consumer discretionary spending on the upswing, beer spending should grow in kind. For TAP specifically, the possibility of a falling dollar bodes well for the firm's large international exposure -- and its ability to hike its payout.

  Right now, TAP pays a 32-cent dividend for a 2.6% yield.

Top 5 Beverage Companies To Own In Right Now: Tsingyuan Brewery Ltd (BEER)

Tsingyuan Brewery Ltd., formerly Sabre Industrial, Inc., incorporated on July 25, 1996, is a manufacturer and distributor of brewer's malt and beer throughout northern and eastern China. The Company has two business lines: brewer's malt and beer production.

The brewer's malt is shipped to brewers in 10 provinces across China. The beer products are distributed throughout six provinces. The Company utilizes the German brewing techniques and uses barley, water and hops. Tsingyuan Brewery Ltd. promotes nine products under its brand names Qinglin, Qingyi, and Qingyuan.

Top 5 Beverage Companies To Own In Right Now: DNA Brands Inc (DNAX)

DNA Brands, Inc. (DNA), incorporated on May 23, 2007, produces, markets and sells a line of four carbonated blends of DNA Energy Drinks, as well as a line of meat snacks made up of two beef jerky flavors and four flavors of beef sticks. These drinks are sold in 16 ounce cans. The beef jerky is packaged in a three ounce sealable pouch and the beef stick is one ounce stick form. Its product flavors include DNA Energy Drink, DNA Beef Jerky and DNA Shred Stix.DNA Energy Drink provides citrus, green, citrus sugar free and cranberry raspberry sugar free flavors DNA Beef Jerk provides original and teriyaki flavors. DNA Shred Stix flavors includes original, pizza, jalapeno and taco.

In Florida, distribution is handled by Grass Roots Beverage Company, Inc. (Grass Roots), its wholly owned subsidiary and select Anheuser Bush distributors. In Southern California distribution is covered by Energized Distribution, Inc. CJW Distributing, a Miller Brewing operation, is responsible for the Wisconsin (Midwest) area.

The Company competes with Jack Link��.

Top 5 Beverage Companies To Own In Right Now: SABMiller PLC (SBMRY)

SABMiller plc, incorporated on March 17, 1998, is a holding company, which has brewing and beverage interests across six continents. The Company together with its subsidiaries is engaged in the manufacture, distribution and sale of beverages. The Company is a brewer with more than 200 beer brands. The Company�� portfolio of brands includes international beers, such as Pilsner Urquell, Peroni Nastro Azzurro, Miller Genuine Draft and Grolsch, as well as local brands, such as Aguila, Castle, Miller Lite, Snow, Tyskie and Victoria Bitter. It is a bottler for the Coca-Cola Company in Africa and Central America. It operates in Latin America, Europe, North America, Africa, Asia Pacific, and South Africa.

Latin America

The Company�� primary brewing and beverage operations cover six countries across South and Central America (Colombia, Ecuador, El Salvador, Honduras, Panama and Peru). The Company is brewer in Argentina, and it exports to Bolivia, Chile and Paraguay. It bottles soft drinks for The Coca-Cola Company in El Salvador and Honduras, and for Pepsico International in Panama.

Europe

The Company�� primary brewing operations cover eight countries: the Czech Republic, Hungary, Italy, Poland, Romania, Slovakia, Spain (Canary Islands) and the Netherlands. A further 16 countries, including Russia, Turkey and the Ukraine are covered in a strategic alliance with Anadolu Efes through brewing, soft drinks or export operations. The Company exports volumes to a further seven European markets, of which the largest are the United Kingdom and Germany.

North America

The Company�� North America segment includes its 58% owned MillerCoors and 100% of Miller Brewing International and the its North American holding companies. The Company�� wholly owned Miller Brewing International business is based in Milwaukee, the United States and exports its brands to Canada and Mexico and throughout the Americas.

Africa

The Compa! ny�� brewing and beverage operations in Africa cover 15 countries. A further 21 are covered through a strategic alliance with the Castel group and it also has an associated undertaking in Zimbabwe. The Company bottles soft drinks for The Coca-Cola Company in 20 of its African markets (in alliance with Castel in 14 of these markets).

Asia Pacific

The Company�� partners with China Resources Enterprise, Limited in China. The Company is engaged in brewing business in India. The Company has operation in Vietnam and it exports to various markets, including South Korea and Singapore.

South Africa

The Company�� South African Breweries (Pty) Ltd (SAB) is South Africa�� producer and distributor of lager and soft drinks. It also exports brands for distribution across Namibia. Its soft drinks division is bottler of products for The Coca-Cola Company. The Company has hotel and gaming interests through its associate, Tsogo Sun Holdings Ltd, a hotel and gaming group in South Africa.

Advisors' Opinion:

• [By Rich Duprey]

  Trying to tap into that market would be a difficult task for anyone, even for�SABMiller� (NASDAQOTH: SBMRY  ) ,�the world's second largest brewer, which is why it undoubtedly figured that by hooking up with Canada's biggest operator, Molson Coors� (NYSE: TAP  ) , with 39% of the beer market, it would have an easier time of getting better distribution. Their MillerCoors joint venture was created in 2007 and mainly distributes beer in the U.S. and Puerto Rico, but it also allows Molson to market and distribute certain Miller brands in Canada.

Top 5 Beverage Companies To Own In Right Now: Marani Brands Inc (MRIB.PK)

Marani Brands, Inc. (Marani), incorporated on May 30, 2001, is engaged in the importation and sale of alcoholic beverage products, primarily Marani Vodka, its flagship product. The Company�� primary business is the business of Margrit Enterprises International, Inc. (MEI), which is in the distribution of wine and spirit products manufactured in Armenia. Marani Vodka is made from winter wheat harvested in Armenia, distilled three times, aged in oak barrels lined with honey and skimmed dried milk, then filtered 25 times. Bottling of the product occurs at the Eraskh distillery in Armenia. On April 4, 2008, the Company, FFBI Merger Sub Corp. and MEI executed, and on April 7, 2008, the parties closed, a three party Merger Agreement.

The Company purchases all of its products from a single supplier, Eraskh Winery, Ltd., under an exclusive distribution agreement with Eraskh, an Armenian manufacturer of wine and other spirits. The new bottles for Marani Vodka are being manufactured in France by Saver Glass Company and China by Universal Group Co., Ltd. and shipped to Armenia to be filled at Eraskh. The Company�� product is being distributed by Southern Wine & Spirits of America, Inc. (SWS), in Southern California, in conjuction with PLCB Pennsylvania and Nevada. SWS is an alcoholic beverage distributor in the United States. The Company has established additional distributors, such as QV Distributors in Arizona and Wein-Baur in Illinois.

The Company competes with Diageo, Pernod Ricard, Bacardi and Brown-Forman.

Top 5 Beverage Companies To Own In Right Now: Attitude Drinks Inc (ATTD)

Attitude Drinks Incorporated (Attitude), incorporated on May 10, 1988, is a brand-development company. The Company focuses on the non-alcoholic single serving beverage business, developing and marketing of milk based products in two segments: sports recovery and functional dairy. The Company does not directly manufacture its products but instead outsources the manufacturing process to third party packers.

Attitude has developed its second product, which is branded as Phase III Recovery is a milk-based protein drink which is available in chocolate and vanilla flavors. The Company�� co-packer for its dairy based product is O-AT-KA Milk Products Cooperative, Inc. in Batavia, New York. This product contains 35 grams of protein that are inherent in filtered milk. The product is packaged as a retort-processed shelf stable dairy-based 100% milk-based sports recovery drink in both chocolate and vanilla flavors.

The Company competes with The Coca-Cola Company and Pepsico Inc.

Advisors' Opinion:

• [By Peter Graham]

  Small cap stocks Attitude Drinks Inc (OTCMKTS: ATTD), Axiologix, Inc (OTCMKTS: AXLX) and Unisource Corporation (OTCMKTS: USRC) have all been getting some attention lately in investment emails or investor alerts thanks in part to paid promotions. And while there is nothing wrong with properly disclosed paid promotions or investor relations activity, such activity can backfire on unwary investors or traders. With that in mind, here is a closer look at all three small cap stocks to help you decide whether they are truly hot or not:

Top 5 Beverage Companies To Own In Right Now: WhiteWave Foods Co (WWAV)

WWF Operating Company, incorporated on March 14, 1988, is a consumer packaged food and beverage company. The Company manufactures, markets, distributes, and sells plant-based foods and beverages, coffee creamers and beverages, and dairy products throughout North America and Europe. The Company operates in two segments: North America and Europe. The North America segment offers products in the plant-based foods and beverages, coffee creamers and beverages, and dairy product categories throughout North America. Europe segment offers plant-based food and beverage products throughout Europe. The Company is a wholly owned subsidiary of Dean Foods Company (Dean Foods).

The Company�� brands distributed in North America include Silk plant-based foods and beverages, International Delight and LAND O LAKES coffee creamers and beverages, and Horizon Organic dairy products, while its European brands of plant-based foods and beverages include Alpro and Provamel. The Company sell its products to a variety of customers, including grocery stores, mass merchandisers, club stores, and convenience stores, as well as various away-from-home channels, including restaurants and foodservice outlets, across North America and Europe. The Company sells its products in North America and Europe primarily through its direct sales force and independent brokers. The Company utilizes five manufacturing plants, two distribution centers, and three co-packers across the United States. Additionally, it has four plants across Europe in the United Kingdom, Belgium, France, and the Netherlands, each supported by an integrated supply chain.

Advisors' Opinion:

• [By Michael Lewis]

  After being spun off from its parent company, Dean Foods (NYSE: DF  ) , health-oriented food purveyor White Wave Foods (NYSE: WWAV  ) offered the market a nearly pure play on plant-based food items, one of the fastest growing areas within the industry. The spinoff was originally priced rather high, though the company is certainly growing. Now, the secondary offering is coming to a close and the spinoff is nearly complete while the company posts strong preliminary results. Even at its premium price, is White Wave Foods a buy after the spin-off is completed?

• [By Pendulum]

  Organic / Health Foods companies:

  Hain Celestial (HAIN)WhiteWave (WWAV)Annie's

  Best In Class Food Companies:

  Coca-Cola (KO)Pepsico (PEP)Mondelez (MDLZ)Kraft Foods (KRFT)General Mills (GIS)Kellogg (K)ConAgra Foods (CAG)Hershey (HSY)J.M. Smucker (SJM)McCormick (MKC)Dean Foods (DF)

  A few comments about this analysis:

Top 5 Beverage Companies To Own In Right Now: Coca-Cola Enterprises Inc. (CCE)

Coca-Cola Enterprises Inc. produces, distributes, and markets non-alcoholic beverages in Europe. It provides a range of beverage categories, including energy drinks, still and sparkling waters, juices, sports drinks, fruit drinks, coffee-based beverages, and teas. The company primarily offers its products under Coca-Cola, Diet Coke/Coke light, Fanta, Coca-Cola Zero, Capri Sun, Schweppes, Sprite, Chaudfontaine, MinuteMaid, and Dr. Pepper brands. It provides its products to customers and consumers through licensed territory agreements in Belgium, continental France, Great Britain, Luxembourg, Monaco, the Netherlands, Norway, and Sweden. Coca-Cola Enterprises Inc. was founded in 1986 and is based in Atlanta, Georgia.

Advisors' Opinion:

• [By Dan Caplinger]

  Indeed, consumer-oriented stocks are among the weakest performers in the Dow today. Coca-Cola (NYSE: KO  ) is down 2%, likely in response to a reduced forecast from independent bottler Coca-Cola Enterprises (NYSE: CCE  ) . The bottling company said continued trouble in the European economy combined with cold, rainy weather throughout much of the region led to volume declines of 2.5% for the quarter, confirming Coca-Cola's own 4% decline in soda sales in North America that it reported last week. Coke investors need to remember that Coke, with its global operations, is not influenced by U.S.-centric consumer figures so much as domestically focused companies.

Top 5 Beverage Companies To Own In Right Now: Alkaline Water Company Inc (WTER.OB)

The Alkaline Water Company Inc., formerly Global Lines Inc, incorporated on June 6, 2011, is a developer of electrolysis beverage process, packaged and branded as Alkaline84. Alkaline84 is the Company's flagship product designed to encourage daily consumption of Alkaline Water through a consumer oriented bulk delivery system. The Company is engaged in the development of a national retail bulk distribution network delivering Electrochemically Activated Water (ECA) to consumers everywhere. The Company is focused on the business of distributing and marketing the retail sale of its packaged Alkaline84 branded beverage products.

Alkaline84 is available in two sizes: three liters and one gallon. Alkaline84 is a pH balanced bottled alkaline drinking water enhanced with 84 trace minerals and electrolytes. Alkaline84 is available for consumer sales at a number of major retail locations across the southwestern United States.

Top 5 Beverage Companies To Own In Right Now: Central European Distribution Corp (CEDCQ)

Central European Distribution Corporation (CEDC), incorporated on September 4, 1997, operates primarily in the alcohol beverage industry. CEDC is a producer of vodka and is Central and Eastern Europe�� integrated spirit beverages business. During the year ended December 31, 2011, as measured by total volume, the Company produced and distributed approximately 33.2 million nine-liter cases . The Company�� business primarily involves the production and sale of its own spirit brands (principally vodka), and the importation on a basis of a range of spirits, wines and beers. Its primary operations are conducted in Poland and Russia. In addition the Company also has operations in Hungary and Ukraine. CEDC has six manufacturing facilities located in Poland and Russia. On February 7, 2011, the Company completed purchasing of the remaining stake of the Whitehall Group.

CEDC is an importer of spirits, wines and beers in Poland, Russia and Hungary. The Company maintains import contracts for a number of internationally recognized brands, including Jim Beam Bourbon, Campari, Jagermeister, Remy Martin Cognac, Corona, Budweiser (Budvar), E&J Gallo wines, Carlo Rossi wines, Sutter Home wines, Metaxa Brandy, Sierra Tequila, Teacher�� Whisky, Cinzano, Old Smuggler, Grant�� Whisky and Concha y Toro wines. In addition to its operations in Poland, Russia, and Hungary the Company has Ukraine and distribution agreements for its vodka brands in a number of key export markets including the United Kingdom, Ukraine, the Baltics and the CIS for Green Mark, Zhuravli, Parliament and Zubrowka, the United States, Japan, the United Kingdom, France for Zubrowka and many other Western European countries. In 2011, exports represented 11% of its sales by value.

Poland

In Poland, CEDC is the vodka producers with a brand portfolio that includes Absolwent, Zubrowka, Zubrowka Biala, Bols, Palace and Soplica brands, each of which it produces at its Polish distilleries. It produces and sells vodka! s primarily in three vodka sectors: premium, mainstream, and economy. The Company owns two production sites in Poland: one in Oborniki and one in Bialystok. In the Oborniki distillery, it produces the Bols and Soplica vodka brands, among other spirit brands. In Bialystok it produces Absolwent and Zubrowka. Zubrowka is also exported out of Poland to many markets around the world, including the United States, England, Japan and also France. In addition to the Absolwent and Zubrowka brands, in Bialystok it produces the Zubrowka Biala brand. The Company has rights to import and distribute approximately 70 brands of spirits, wine and beer into Poland. It also provides marketing support to the suppliers. During 2011, the Company sold approximately 10.7 million nine-liter cases of vodka, wine and spirits through its Polish business during 2011 including both its own produced vodka brands as well as its exclusive agency import brands. During 2011, the Company sold approximately 191 thousand nine-liter cases of Zubrowka outside of Poland. During 2011, the Company�� Polish operations accounted for 26.3% of its revenue.

Russia

CEDC produces Green Mark in Russia and the sub-premium vodkas in Russia, Parliament and Zhuravli. During 2011 the Company introduced new brands to the Russian market Talka, Sotka and Silver Blend. The Company also produces Yamskaya, the economy vodka in Russia, and premixed alcohol drinks, or long drinks. The Company also owns Whitehall, which holds the exclusive rights to the import of such leading premium wine and spirit brands as Concha y Toro, Paul Masson, Robert Mondavi, DeKuyper, Jose Cuervo and Label 5. In addition to these import activities, Whitehall has distribution centers in Moscow, Saint Petersburg, and Rostov as well as a wine and spirits retail network located in Moscow. During 2011, the Company�� Russian operations accounted for 70.2% of its revenue. During 2011,the Company produced and sold approximately 16.6 million nine-liter cases of vodka th! rough its! Russian business in the main vodka segments in Russia: premium, sub-premium, mainstream, economy and cheap. In addition it produced and sold approximately 2.8 million nine-liter cases of long drinks.

Hungary

The Company sells Royal Vodka in Hungary through its Bols Hungary subsidiary. The imported brands to Hungary include Bols Vodka, Zubrowka, Royal Vodka, Campari, Cinzano, Jaegermeister, Bols Liqueurs, Cointreau, Carolans, Galliano, Irish Mist, Jose Cuervo, Calvados Boulard, Remy Martin, Metaxa, St Remy, Grant��, Glenfiddich, Tullamore Dew and Old Smuggler.